Results 321 to 330 of about 164,448 (358)

Omalizumab reduces anaphylactic reactions and allows food introduction in food‐allergic in children with severe asthma: An observational study

open access: yesAllergy, Volume 80, Issue 4, Page 1074-1085, April 2025.
In Europe, Omalizumab is indicated for the treatment of moderate to severe asthma, but not for IgE‐mediated food allergy. We assessed the impact of Omalizumab on efficacy, safety, and the quality of life (FA‐QoL) in patients with moderate to severe asthma and who have a history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat.
Stefania Arasi   +14 more
wiley   +1 more source

Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition

open access: yes
The Journal of Dermatology, EarlyView.
Yoshihide Asano   +27 more
wiley   +1 more source

Effects of Surface Charge of Inhaled Liposomes on Drug Efficacy and Biocompatibility. [PDF]

open access: yesPharmaceutics
Zhang J   +6 more
europepmc   +1 more source

Lung volume assessment for mean dark-field coefficient calculation using different determination methods. [PDF]

open access: yesEur Radiol Exp
Gassert FT   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy